Marking five years of polio-free certification

S Singh
S Singh
· 3 min read
Khetrapal

On this day in 2014, WHO South-East Asia Region was certified polio-free, proving wrong many public health experts who believed that the Region, which accounts for one-fourth of the global population, would be the last bastion for polio eradication. Five years on, the Region not only continues to maintain its polio-free status but is demonstrating how the polio legacy can effectively strengthen overall immunization and other programs.

“Member countries, partners and the community themselves continue to work together to keep the crippling virus at bay. The polio program’s emphasis on innovation and reaching everyone, everywhere is being replicated by many other public health programs with impressive results,” said Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region.

The last case of wild poliovirus in the Region was reported from West Bengal, India, where a two-year old girl suffered polio paralysis on 13 January 2011.  An intense response by Government of India supported by WHO, UNICEF, Rotary International and other partners ensured it remained the last case in WHO South-East Asia Region.

Post certification, these efforts continue. Every year, more than 32 million children across the Region are being reached with oral polio vaccines under routine immunization and through mass polio vaccination campaigns to maintain high population immunity against polio. In India, an additional 460 million doses of oral polio vaccines were given to children through four mass polio vaccination campaigns conducted in 2018.

As a part of the vigilance for polio in the Region, surveillance for polio continues to be further strengthened. More than 75 000 stool samples were tested in 16 poliovirus laboratories in the Region in 2018. Environmental surveillance for poliovirus detection has been expanded three-fold in the last five years. Samples are now collected for testing from 74 sites in India, Indonesia, Bangladesh, Nepal, Myanmar and Thailand. In 2014, environment surveillance was conducted only in India, from 23 sites.

While continuing to maintain a strict vigil against polio, the entire polio machinery in the Region is also geared towards strengthening routine immunization to further boost defense against polio as well as other vaccine preventable diseases. There has been a steady progress in immunization coverage of the basic vaccines provided in the first year of life.  Nearly 88% children in the Region are receiving three doses of the basic vaccines before they achieve the age of one year. In seven of the 11 countries, this coverage is over 90%. All countries have introduced at least two new vaccines under their routine immunization program to protect children from vaccine preventable diseases.

Polio programme and its lessons are guiding efforts to eliminate measles and control rubella, a flagship priority programme in WHO South-East Asia Region.

The polio networks are also supporting countries to strengthen vaccine preventable disease surveillance.

“This day is a reminder of our momentous victory against polio, a reminder of our commitment to health of our children, and a reminder of our potential, of our determination to turn impossible into possible,” the Regional Director said.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk